JP2005532371A - レニン阻害剤としての新規なテトラヒドロピリジン誘導体 - Google Patents

レニン阻害剤としての新規なテトラヒドロピリジン誘導体 Download PDF

Info

Publication number
JP2005532371A
JP2005532371A JP2004516551A JP2004516551A JP2005532371A JP 2005532371 A JP2005532371 A JP 2005532371A JP 2004516551 A JP2004516551 A JP 2004516551A JP 2004516551 A JP2004516551 A JP 2004516551A JP 2005532371 A JP2005532371 A JP 2005532371A
Authority
JP
Japan
Prior art keywords
phenyl
tetrahydropyridine
carboxylic acid
ethoxy
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004516551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532371A5 (enExample
Inventor
ベゼンコン オリヴィエ
ブル ダニエル
ウオルター フィシュリ
リーメン ルーボス
リチャード−ビィルドスタイン シルビア
ウィラー トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2005532371A publication Critical patent/JP2005532371A/ja
Publication of JP2005532371A5 publication Critical patent/JP2005532371A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004516551A 2002-06-27 2003-04-29 レニン阻害剤としての新規なテトラヒドロピリジン誘導体 Pending JP2005532371A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0207102 2002-06-27
PCT/EP2003/004445 WO2004002957A1 (en) 2002-06-27 2003-04-29 Novel tetrahydropyridine derivatives as renin inhibitors

Publications (2)

Publication Number Publication Date
JP2005532371A true JP2005532371A (ja) 2005-10-27
JP2005532371A5 JP2005532371A5 (enExample) 2006-06-29

Family

ID=29797098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004516551A Pending JP2005532371A (ja) 2002-06-27 2003-04-29 レニン阻害剤としての新規なテトラヒドロピリジン誘導体

Country Status (16)

Country Link
US (1) US20060009497A1 (enExample)
EP (1) EP1519920A1 (enExample)
JP (1) JP2005532371A (enExample)
CN (1) CN1662498A (enExample)
AU (1) AU2003229746A1 (enExample)
BR (1) BR0312000A (enExample)
CA (1) CA2490138A1 (enExample)
CL (1) CL2003002043A1 (enExample)
IL (1) IL165887A0 (enExample)
MX (1) MXPA04012136A (enExample)
NO (1) NO20050290L (enExample)
PL (1) PL375214A1 (enExample)
RU (1) RU2005102002A (enExample)
TW (1) TW200514772A (enExample)
WO (1) WO2004002957A1 (enExample)
ZA (1) ZA200408423B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523845A (ja) * 2003-04-29 2007-08-23 アクテリオン ファマシューティカルズ リミテッド 新規3,4−ジ置換1,2,3,6−テトラヒドロピリジン誘導体
JP2009529033A (ja) * 2006-03-08 2009-08-13 アクテリオン ファーマシューティカルズ リミテッド 新規アミン

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217371A1 (en) * 2003-04-28 2006-09-28 Olivier Bezencon Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors
AU2004233575A1 (en) * 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd 9-azabicyclo'3.3.1!non-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
RU2005137571A (ru) * 2003-05-02 2006-05-10 Актелион Фармасьютикалз Лтд. (Ch) Новые производные диазабициклононена
WO2004105738A2 (en) * 2003-05-30 2004-12-09 Actelion Pharmaceuticals Ltd Use of tetrahydropyridine derivatives
CN1863773A (zh) * 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
US20070142363A1 (en) * 2003-10-13 2007-06-21 Actelion Pharmaceuticals Ltd Novel diazabicyclonene derivatives and use thereof
WO2005054243A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
CA2552965A1 (en) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited Carboxamide derivative and use thereof
NZ586285A (en) * 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
JP2008510755A (ja) 2004-08-25 2008-04-10 アクテリオン ファーマシューティカルズ リミテッド ビシクロノネン誘導体
GB0428526D0 (en) * 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) * 2005-03-09 2005-04-13 Novartis Ag Organic compounds
GB0510810D0 (en) * 2005-05-26 2005-06-29 Novartis Ag Organic compounds
KR100963455B1 (ko) * 2005-05-27 2010-06-18 액테리온 파마슈티칼 리미티드 신규한 피페리딘 카르복실산 아미드 유도체
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
WO2007049224A1 (en) * 2005-10-25 2007-05-03 Actelion Pharmaceuticals Ltd Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives
JP2009526767A (ja) 2006-02-02 2009-07-23 アクテリオン ファーマシューティカルズ リミテッド 新規二級アミン
AU2007220149A1 (en) * 2006-03-03 2007-09-07 Actelion Pharmaceuticals Ltd Primary amines as renin inhibitors
EP1908471A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
EP2162436A4 (en) 2007-05-24 2010-08-04 Merck Frosst Canada Ltd NEW CASE OF RENININHIBITORS
CA2696689A1 (en) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
CN102015682B (zh) 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物
ES2645725T3 (es) 2010-06-11 2017-12-07 Rhodes Technologies Procesos catalizados por metales de transición para la preparación de compuestos de N-alilo y uso de los mismos
WO2011154826A1 (en) 2010-06-11 2011-12-15 Rhodes Technologies Process for n-dealkylation of tertiary amines
CN117865941B (zh) * 2024-03-13 2024-06-28 上海方予健康医药科技有限公司 取代哌啶化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
KR100384979B1 (ko) * 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523845A (ja) * 2003-04-29 2007-08-23 アクテリオン ファマシューティカルズ リミテッド 新規3,4−ジ置換1,2,3,6−テトラヒドロピリジン誘導体
JP2009529033A (ja) * 2006-03-08 2009-08-13 アクテリオン ファーマシューティカルズ リミテッド 新規アミン

Also Published As

Publication number Publication date
CA2490138A1 (en) 2004-01-08
CN1662498A (zh) 2005-08-31
MXPA04012136A (es) 2005-04-19
TW200514772A (en) 2005-05-01
AU2003229746A1 (en) 2004-01-19
PL375214A1 (en) 2005-11-28
ZA200408423B (en) 2005-10-11
NO20050290L (no) 2005-01-19
US20060009497A1 (en) 2006-01-12
EP1519920A1 (en) 2005-04-06
WO2004002957A1 (en) 2004-01-08
RU2005102002A (ru) 2005-09-20
BR0312000A (pt) 2005-03-22
CL2003002043A1 (es) 2005-01-28
IL165887A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
JP2005532371A (ja) レニン阻害剤としての新規なテトラヒドロピリジン誘導体
EP0930298B1 (en) Fluorinated 1,4-disubstituted piperidine derivatives
US5750540A (en) 1,4-di-substituted piperidine derivatives
DE69534164T2 (de) Tri-substituierte phenyl-derivate verwendbar als pde iv hemmer
JP4041123B2 (ja) 新規なジアザビシクロノネン
TWI864071B (zh) 2-羥環烷-1-胺甲醯基衍生物
JPWO1998005641A1 (ja) 含フッ素1,4−ジ置換ピペリジン誘導体
JP2007508260A (ja) 新規なテトラヒドロピリジン誘導体
JP2006524655A (ja) 3−位にヘテロ原子を有する新規9−アザビシクロノネン誘導体
JP2006525259A (ja) 新規ジアザビシクロノネン誘導体
JP2006524656A (ja) 新規ジアザビシクロノネンおよびテトラヒドロピリジン誘導体
JP2007513107A (ja) ジアザビシクロノネンおよび新側鎖を有するテトラヒドロピリジン誘導体
JP2006524654A (ja) 新規アザビシクロノネン誘導体
JP2015531398A (ja) アルドステロンシンターゼインヒビター関連用途としてのインドリン化合物
JP2007523845A (ja) 新規3,4−ジ置換1,2,3,6−テトラヒドロピリジン誘導体
JP2006524657A (ja) 新規トロパン誘導体
KR101854152B1 (ko) S1p1 수용체 작용제로서의 신규의 피페리디닐 모노카르복실산
JP2012511514A (ja) レニン阻害剤としての3,4−置換ピペリジン誘導体
JP2000219678A (ja) ベンゼン誘導体又はピリジン誘導体
JP2007509099A (ja) 新規ジアザビシクロノネンおよび新規極性側鎖を有するテトラヒドロピリジン誘導体
JP2007508262A (ja) 新規ジアザビシクロノネン誘導体およびその使用
JP2007513106A (ja) 新規ジアザビシクロノネン誘導体およびその使用
JPWO2005118556A1 (ja) プロパン−1,3−ジオン誘導体又はその塩
WO1996035667A1 (en) Alpha-(substituted alkylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidine butanol derivatives, their preparation and their use as anti-histamines, anti-allergy agents and bronchodilators
KR20050019759A (ko) 레닌 억제제로서의 신규한 테트라하이드로피리딘 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100415